FindTrial
Sign In

HRS-6209

DRUG3 trials

Sponsors

Fudan University, Jiangsu HengRui Medicine Co., Ltd., Shandong Suncadia Medicine Co., Ltd.

Conditions

Advanced Solid TumorsAdvanced Unresectable or Metastatic Breast CancerBreast CancerBreast NeoplasmBreast TumorsEarly-stage Breast CancerHER2-negative Breast CancerHER2-positive Breast Cancer

Phase 1

A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
Active, not recruitingNCT05781048
Jiangsu HengRui Medicine Co., Ltd.Advanced Solid Tumors
Start: 2023-03-23End: 2026-12-30Updated: 2026-03-10
A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
RecruitingNCT06679036
Shandong Suncadia Medicine Co., Ltd.Advanced Unresectable or Metastatic Breast Cancer
Start: 2025-01-21End: 2026-12-31Target: 300Updated: 2026-03-02

Phase 2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
RecruitingNCT05582499
Fudan UniversityBreast Cancer, Breast Neoplasm, Breast Tumors +7
Start: 2022-11-01End: 2029-09-01Target: 716Updated: 2026-05-28

Related Papers

Abstract GS1-04: HER2-Directed Antibody-Drug Conjugate SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer: a Prospective, Randomized, Open-label, Phase 2 Trial
Clinical Cancer Research2025-06-13
Abstract P2-11-06: Neoadjuvant chemotherapy plus camrelizumab vs. chemotherapy in patients with locally advanced immunomodulatory triple-negative breast cancer: a prospective, randomized, open-label, phase 2 trial
Clinical Cancer Research2025-06-13
Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial
Therapeutic Advances in Medical Oncology2024-01-017 citations